Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Bortezomib in Advanced Soft Tissue Sarcomas
NCT00937495Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2009
- Primary completion
- Aug 2010
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, bortezomib in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Started Jun 2009; status: completed.
02
Drugs
vorinostatbortezomib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00937495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00937495.